Nocion Therapeutics, whose taplucainium (NTX-1175) DPI is in Phase 2 development for the treatment of chronic cough, has announced the appointments of two former Bellus Health executives, naming Catherine Bonuccelli to the scientific advisory board and Joan Shaw as Senior VP, Clinical Operations. Both were involved in the clinical development of Bellus’ camlipixant for chronic cough prior to that company’s acquisition by GSK in 2023.
Bonuccelli was most recently Chief Medical Officer of Bellus Health; was previously VP, Respiratory Therapy Area Head, at GSK; and served in a number of roles at AstraZeneca, including as Clinical VP for respiratory and inflammation areas and as Global Product VP for Symbicort. Shaw was Senior VP of Clinical Operation at Bellus Health and previously held executive roles at a number of companies, including AstraZeneca, Quotient, Parexel, and UBC.
Nocion CEO Rick Batycky commented, “We are delighted to welcome Cathy and Joan to our scientific/clinical teams as we prepare for the start of our ASPIRE Phase 2b clinical trial of taplucainium in 240 chronic cough patients in the second half of 2024. Catherine and Joan each have unique and successful experiences in the area of therapeutic development for chronic cough. These experiences are immediately applicable to our development of taplucainium for patients suffering from chronic cough.”
Read the Nocion Therapeutics press release.
